{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:26:23Z","timestamp":1790637983418,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.pnpbp.2024.111213","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T16:49:07Z","timestamp":1733503747000},"page":"111213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Comparative safety of prescribed Esketamine and ketamine in relation to renal and urinary disorders: A pharmacovigilance perspective"],"prefix":"10.1016","volume":"136","author":[{"given":"S.","family":"Chiappini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Guirguis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Schifano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Corkery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Semeraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Duccio Papanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Arillotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Floresta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Martinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Schifano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pnpbp.2024.111213_bb0005","doi-asserted-by":"crossref","first-page":"38247","DOI":"10.52965\/001c.38247","article-title":"Ketamine-induced cystitis: a comprehensive review of the urologic effects of this psychoactive drug","volume":"10","author":"Anderson","year":"2022","journal-title":"Health Psychol. Res."},{"key":"10.1016\/j.pnpbp.2024.111213_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112027","article-title":"An association between incontinence and antipsychotic drugs: a systematic review","volume":"142","author":"Arasteh","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111213_bb0015","first-page":"340","article-title":"Intranasal Esketamine (SpravatoTM) for use in treatment-resistant depression in conjunction with an Oral antidepressant","volume":"44","author":"Bahr","year":"2019","journal-title":"P T."},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111213_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpath.2015.12.014","article-title":"Ketamine-induced apoptosis in Normal human urothelial cells","volume":"186","author":"Baker","year":"2016","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.pnpbp.2024.111213_bb0025","doi-asserted-by":"crossref","DOI":"10.1111\/bju.16404","article-title":"Neurological and urodynamic urology. British association of urological surgeons consensus statements on the management of ketamine uropathy","author":"Belal","year":"2024","journal-title":"BJU Int."},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111213_bb0030","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.therap.2020.02.022","article-title":"Uses of pharmacovigilance databases: an overview","volume":"75","author":"Bihan","year":"2020","journal-title":"Therapie"},{"issue":"7","key":"10.1016\/j.pnpbp.2024.111213_bb0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.22056","article-title":"Absolute and relative risks of kidney outcomes associated with Lithium vs valproate use in Sweden","volume":"6","author":"Bosi","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"12","key":"10.1016\/j.pnpbp.2024.111213_bb0040","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.3390\/pharmaceutics15122773","article-title":"The efficacy and safety of intranasal formulations of ketamine and Esketamine for the treatment of major depressive disorder: a systematic review","volume":"15","author":"Boudieu","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111213_bb0045","article-title":"Ketamine-induced acute interstitial nephritis","volume":"8","author":"Brucculeri","year":"2023","journal-title":"Kidney Int. Rep."},{"issue":"8","key":"10.1016\/j.pnpbp.2024.111213_bb0055","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40263-023-01026-3","article-title":"Efficacy and safety of Esketamine nasal spray in patients with treatment-resistant depression who completed a second induction period: analysis of the ongoing SUSTAIN-3 study","volume":"37","author":"Castro","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2024.111213_bb0065","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.euroneuro.2023.04.011","article-title":"Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: a viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study","volume":"74","author":"Chiappini","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"11","key":"10.1016\/j.pnpbp.2024.111213_bb0070","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/j.1464-410X.2008.07920.x","article-title":"The destruction of the lower urinary tract by ketamine abuse: a new syndrome?","volume":"102","author":"Chu","year":"2008","journal-title":"BJU Int."},{"issue":"9","key":"10.1016\/j.pnpbp.2024.111213_bb0080","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of Esketamine nasal spray plus Oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"10.1016\/j.pnpbp.2024.111213_bb0085","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40263-022-00952-y","article-title":"Psychotropic drugs and adverse kidney effects: a systematic review of the past decade of research","volume":"36","author":"Damba","year":"2022","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111213_bb0090","article-title":"Intranasal esketamine as tool for rapid cycling bipolar disorder: a case report of successful mood stabilization","volume":"2","author":"D\u2019Andrea","year":"2023","journal-title":"Psychiatry Res. Case Rep."},{"key":"10.1016\/j.pnpbp.2024.111213_bb0095","first-page":"70","article-title":"Rethinking ketamine and esketamine action: are they antidepressants with mood-stabilizing properties?","author":"D\u2019Andrea","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.pnpbp.2024.111213_bb0100","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3390\/ph16071031","article-title":"Lower urinary tract disorders as adverse drug reactions\u2014a literature review","volume":"16","author":"Dobrek","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"8","key":"10.1016\/j.pnpbp.2024.111213_bb0105","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/nau.22851","article-title":"Linking the evidence between urinary retention and antipsychotic or antidepressant drugs: a systematic review","volume":"35","author":"Faure Walker","year":"2016","journal-title":"Neurourol.Urodyn."},{"key":"10.1016\/j.pnpbp.2024.111213_bb0110","author":"FDA"},{"issue":"10","key":"10.1016\/j.pnpbp.2024.111213_bb0115","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose Esketamine nasal spray combined with a new Oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"11","key":"10.1016\/j.pnpbp.2024.111213_bb0120","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-020-05611-y","article-title":"Urothelial toxicity of esketamine in the treatment of depression","volume":"237","author":"Findeis","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"issue":"11","key":"10.1016\/j.pnpbp.2024.111213_bb0125","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1007\/s00213-020-05611-y","article-title":"Urothelial toxicity of esketamine in the treatment of depression","volume":"237","author":"Findeis","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111213_bb0130","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1523\/JNEUROSCI.0373-14.2015","article-title":"The role of brain-derived neurotrophic factor (BDNF) in the development of neurogenic detrusor overactivity (NDO)","volume":"35","author":"Frias","year":"2015","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111213_bb0135","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4103\/tcmj.tcmj_94_23","article-title":"Pathophysiology, clinical presentation, and management of ketamine-induced cystitis","volume":"35","author":"Jhang","year":"2023","journal-title":"Tzu Chi. Med. J."},{"key":"10.1016\/j.pnpbp.2024.111213_bb0140","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","article-title":"Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study)","volume":"319","author":"Martinotti","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111213_bb0145","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40263-018-0519-3","article-title":"Antidepressant efficacy and tolerability of ketamine and Esketamine: a critical review","volume":"32","author":"Molero","year":"2018","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111213_bb0150","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00213-021-05767-1","article-title":"Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment","volume":"238","author":"Ng","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111213_bb0155","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","article-title":"Efficacy and safety of Esketamine nasal spray plus an Oral antidepressant in elderly patients with treatment-resistant depression\u2014TRANSFORM-3","volume":"28","author":"Ochs-Ross","year":"2020","journal-title":"Am. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.pnpbp.2024.111213_bb0160","doi-asserted-by":"crossref","DOI":"10.1007\/s00228-024-03714-5","article-title":"Risk of renal impairment in atypical antipsychotics: a systematic review and meta-analysis","author":"Ong","year":"2024","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111213_bb0165","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111213_bb0170","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s11606-007-0453-4","article-title":"Evidence-based medicine teaching tips working group. Tips for teachers of evidence-based medicine: understanding odds ratios and their relationship to risk ratios","volume":"23","author":"Prasad","year":"2008","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.pnpbp.2024.111213_bb0175","doi-asserted-by":"crossref","DOI":"10.1177\/2042098620937899","article-title":"Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review","volume":"11","author":"Salahudeen","year":"2020","journal-title":"Ther. Adv. Drug Saf."},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111213_bb0180","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/luts.12355","article-title":"Is medicinal ketamine associated with urinary dysfunction issues? Assessment of both the European medicines agency (EMA) and the UK yellow card scheme pharmacovigilance database-related reports","volume":"13","author":"Schifano","year":"2021","journal-title":"Low Urin Tract Symptoms."},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111213_bb0185","first-page":"227","article-title":"Explaining odds ratios [published correction appears in J Can Acad Child Adolesc Psychiatry. 2015 Winter;24(1):58]","volume":"19","author":"Szumilas","year":"2010","journal-title":"J. Can. Acad. Child Adolesc. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111213_bb0190","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/nau.24695","article-title":"Urinary side effects of psychotropic drugs: a systematic review and metanalysis","volume":"40","author":"Trinchieri","year":"2021","journal-title":"Neurourol.Urodyn."},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111213_bb0195","doi-asserted-by":"crossref","first-page":"19m12891","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a Phase 3, open-label study (SUSTAIN-2)","volume":"81","author":"Wajs","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2024.111213_bb0200","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jpsychires.2021.10.026","article-title":"Urological adverse drug reactions of psychotropic medication in psychiatric inpatients - a drug surveillance report from German-speaking countries","volume":"144","author":"Winkler","year":"2021","journal-title":"J. Psychiatr. Res."},{"issue":"7","key":"10.1016\/j.pnpbp.2024.111213_bb0210","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3390\/toxics9070154","article-title":"Intravesical instillation of norketamine, a ketamine metabolite, and induced bladder functional changes in rats","volume":"9","author":"Yeh","year":"2021","journal-title":"Toxics"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584624002811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584624002811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T15:28:18Z","timestamp":1745854098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584624002811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":38,"alternative-id":["S0278584624002811"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2024.111213","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative safety of prescribed Esketamine and ketamine in relation to renal and urinary disorders: A pharmacovigilance perspective","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2024.111213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111213"}}